New combo therapy takes on deadly brain cancer
NCT ID NCT05879250
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tests a drug called WP1066 combined with radiation therapy for people with a newly diagnosed aggressive brain cancer called glioblastoma. The drug targets a protein that helps the tumor grow and hide from the immune system, while radiation kills cancer cells. The goal is to see if this combination can stop the tumor from growing and help people live longer. About 39 adults with a specific type of glioblastoma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern Medicine: Warrenville
ACTIVE_NOT_RECRUITINGWarrenville, Illinois, 60555, United States
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.